Preliminary revenue from biopharma and other customers is estimated to be $15.8 million in the fourth quarter of 2022 compared with $15.4 million in the fourth quarter of 2021, and preliminary revenue from biopharma and other customers includes estimated revenue from Natera at $8.2 million in the fourth quarter of 2022. Interim CEO Aaron Tachibana says: "We ended 2022 by exceeding our previous full year guidance range, driven by oncology revenue growth of 42% for the fiscal year. We will be providing details in the coming weeks about extending our cash runway while focusing on our key product opportunities."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PSNL: